Crossref
In Brief: Extended Duration of Use for Nexplanon
The Medical Letter on Drugs and Therapeutics · 02.03.2026 · 68 (1749) · 40-40
DOI: 10.58347/tml.2026.1749b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 02.03.2026.
Abstract (Originalsprache)
Nexplanon, a single-rod contraceptive implant containing the progestin etonogestrel, has now been approved for prevention of pregnancy for up to 5 years. It was previously approved for up to 3 years of use.
Schlagwörter
Stichwörter der Autor:innen
Nexplanoncontraceptivesefficacyetonogestrel
Zitieren
APA
(2026). In Brief: Extended Duration of Use for Nexplanon. The Medical Letter on Drugs and Therapeutics, 68(1749), 40-40. https://doi.org/10.58347/tml.2026.1749b
Vancouver
In Brief: Extended Duration of Use for Nexplanon. The Medical Letter on Drugs and Therapeutics. 2026;68(1749):40-40. doi:10.58347/tml.2026.1749b
BibTeX
@article{euvimed2026,
title = {In Brief: Extended Duration of Use for Nexplanon},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1749},
pages = {40--40},
doi = {10.58347/tml.2026.1749b}
}
EUVIMED